The counter regulatory response induced by CpG oligonucleotides prevents bleomycin induced pneumopathy

Respiratory Research

Volumn 13, Issue , 2012, Pages

  Kinjo, Takeshi ^a   Tomaru, Koji ^a   Haines, Diana C ^a   Klinman, Dennis M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bleomycin; CpG oligonucleotide; Fibrosis; Pneumonitis

Indexed keywords

BLEOMYCIN; CHEMOKINE; CPG OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 2; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; OLIGODEOXYRIBONUCLEOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DOWN REGULATION; FEMALE; LEUKOCYTE; LUNG FIBROSIS; LUNG TOXICITY; MORTALITY; MOUSE; NONHUMAN; PNEUMONIA; THERAPY DELAY; TREATMENT DURATION; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG CONTRAINDICATION; PATHOLOGY;

ANIMALS; BLEOMYCIN; FEMALE; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; PNEUMONIA; PULMONARY FIBROSIS;

EID: 84862269541     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-13-47     Document Type: Article

References (37)

1. Moroni M, Giannetta L, Gelosa G, Secondino S, Chillura G, Colombo E, Siena S. Second-line chemotherapy with bleomycin, methotrexate, and vinorelbine (BMV) for patients with squamous cell carcinoma of the head, neck and esophagus (SCC-HN&E) pretreated with a cisplatin-containing regimen: a phase II study. J Chemother 2003, 15(4):394-399.
2. Canellos GP. Lymphoma: present and future challenges. Semin Hematol 2004, 41(4 Suppl 7):26-31.
3. Rimmer Y, Chester J, Joffe J, Stark D, Shamash J, Powles T, White J, Wason J, Parashar D, Armstrong G, Mazhar D, Williams MV. Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour. Br J Cancer 2011, 105(6):766-772. 10.1038/bjc.2011.309, 21847130.
4. Sausville EA, Stein RW, Peisach J, Horwitz SB. Properties and products of the degradation of DNA by bleomycin and iron(II). Biochemistry 1978, 17(14):2746-2754. 10.1021/bi00607a008, 80227.
5. Sausville EA, Peisach J, Horwitz SB. Effect of chelating agents and metal ions on the degradation of DNA by bleomycin. Biochemistry 1978, 17(14):2740-2746. 10.1021/bi00607a007, 80226.
6. Burger RM, Peisach J, Horwitz SB. Activated bleomycin. A transient complex of drug, iron, and oxygen that degrades DNA. J Biol Chem 1981, 256(22):11636-11644.
7. Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001, 120(2):617-624. 10.1378/chest.120.2.617, 11502668.
8. Santrach PJ, Askin FB, Wells RJ, Azizkhan RG, Merten DF. Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma. Cancer 1989, 64(4):806-811. 10.1002/1097-0142(19890815)64:4<806::AID-CNCR2820640407>3.0.CO;2-X, 2472865.
9. Holoye PY, Luna MA, MacKay B, Bedrossian CW. Bleomycin hypersensitivity pneumonitis. Ann Intern Med 1978, 88(1):47-49.
10. Carnevale-Schianca F, Gallo S, Rota-Scalabrini D, Sangiolo D, Fizzotti M, Caravelli D, Capaldi A, Anselmetti G, Palesandro E, D'Ambrosio L, Coha V, Obert R, Aglietta M, Grignani G. Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin's lymphoma: hope for severe chemotherapy-induced toxicity?. J Clin Oncol 2011, 29(24):e691-e693. 10.1200/JCO.2011.35.6733, 21709191.
11. Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005, 23(30):7614-7620. 10.1200/JCO.2005.02.7243, 16186594.
12. Lewis BM, Izbicki R. Routine pulmonary function tests during bleomycin therapy. Tests may be ineffective and potentially misleading. J Am Med Assoc 1980, 243(4):347-351.
13. Gasse P, Mary C, Guenon I, Noulin N, Charron S, Schnyder-Candrian S, Schnyder B, Akira S, Quesniaux VF, Lagente V, Ryffel B, Couillin I. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest 2007, 117(12):3786-3799. 2066195, 17992263.
14. Gasse P, Riteau N, Charron S, Girre S, Fick L, Petrilli V, Tschopp J, Lagente V, Quesniaux VF, Ryffel B, Couillin I. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med 2009, 179(10):903-913. 10.1164/rccm.200808-1274OC, 19218193.
15. Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med 2011, 208(7):1339-1350. 10.1084/jem.20110551, 3136685, 21727191.
16. Wilson MS, Madala SK, Ramalingam TR, Gochuico BR, Rosas IO, Cheever AW, Wynn TA. Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med 2010, 207(3):535-552. 10.1084/jem.20092121, 2839145, 20176803.
17. Gasse P, Riteau N, Vacher R, Michel ML, Fautrel A, Di PF, Fick L, Charron S, Lagente V, Eberl G, Le BM, Quesniaux VF, Huaux F, Leite-de-Moraes M, Ryffel B, Couillin I. IL-1 and IL-23 mediate early IL-17A production in pulmonary inflammation leading to late fibrosis. PLoS One 2011, 6(8):e23185. 10.1371/journal.pone.0023185, 3156735, 21858022.
18. Mi S, Li Z, Yang HZ, Liu H, Wang JP, Ma YG, Wang XX, Liu HZ, Sun W, Hu ZW. Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms. J Immunol 2011, 187(6):3003-3014. 10.4049/jimmunol.1004081, 21841134.
19. Kradin RL, Sakamoto H, Jain F, Zhao LH, Hymowitz G, Preffer F. IL-10 inhibits inflammation but does not affect fibrosis in the pulmonary response to bleomycin. Exp Mol Pathol 2004, 76(3):205-211. 10.1016/j.yexmp.2003.12.010, 15126102.
20. Krieg AM, Yi A, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374:546-548. 10.1038/374546a0, 7700380.
21. Hemmi H, Takeuchi O, Kawai T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745. 10.1038/35047123, 11130078.
22. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004, 4(4):249-258. 10.1038/nri1329, 15057783.
23. Klaschik S, Tross D, Klinman DM. Inductive and suppressive networks regulate TLR9-dependent gene expression in vivo. J Leukocyte Biol 2009, 85(5):788-795. 10.1189/jlb.1008671, 2669411, 19179452.
24. Klaschik S, Tross D, Shirota H, Klinman DM. Short- and long-term changes in gene expression mediated by the activation of TLR9. Mol Immunol 2010, 47(6):1317-1324. 10.1016/j.molimm.2009.11.014, 2830361, 20005572.
25. Yi AK, Yoon JG, Yeo SJ, Hong SC, English BK, Krieg AM. Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response. J Immunol 2002, 168(9):4711-4720.
26. Crabtree TD, Jin L, Raymond DP, Pelletier SJ, Houlgrave CW, Gleason TG, Pruett TL, Sawyer RG. Preexposure of murine macrophages to CpG oligonucleotide results in a biphasic tumor necrosis factor alpha response to subsequent lipopolysaccharide challenge. Infect Immun 2001, 69(4):2123-2129. 10.1128/IAI.69.4.2123-2129.2001, 98138, 11254566.
27. Sur S, Wild JS, Choudhury BK, Alam R, Sur N, Klinman DM. Long-term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol 1999, 162:6284-62912.
28. Klinman DM, Yi A, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12 and IFNg. Proc Natl Acad Sci USA 1996, 93:2879-2883. 10.1073/pnas.93.7.2879, 39727, 8610135.
29. Knuefermann P, Baumgarten G, Koch A, Schwederski M, Velten M, Ehrentraut H, Mersmann J, Meyer R, Hoeft A, Zacharowski K, Grohe C. CpG oligonucleotide activates Toll-like receptor 9 and causes lung inflammation in vivo. Respir Res 2007, 8:72. 10.1186/1465-9921-8-72, 2173891, 17925007.
30. Luckhardt TR, Coomes SM, Trujillo G, Stoolman JS, Vannella KM, Bhan U, Wilke CA, Moore TA, Toews GB, Hogaboam C, Moore BB. TLR9-induced interferon beta is associated with protection from gammaherpesvirus-induced exacerbation of lung fibrosis. Fibrogenesis Tissue Repair 2011, 4:18. 10.1186/1755-1536-4-18, 3163187, 21810214.
31. Keane MP, Belperio JA, Burdick MD, Strieter RM. IL-12 attenuates bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2001, 281(1):L92-L97.
32. Stevens SL, Ciesielski TM, Marsh BJ, Yang T, Homen DS, Boule JL, Lessov NS, Simon RP, Stenzel-Poore MP. Toll-like receptor 9: a new target of ischemic preconditioning in the brain. J Cereb Blood Flow Metab 2008, 28(5):1040-1047. 10.1038/sj.jcbfm.9600606, 3037270, 18183029.
33. Marsh BJ, Stevens SL, Hunter B, Stenzel-Poore MP. Inflammation and the emerging role of the toll-like receptor system in acute brain ischemia. Stroke 2009, 40(3 Suppl):S34-S37. 2729591, 19064776.
34. Schwartz DA, Wohlford-Lenane CL, Quinn TJ, Krieg AM. Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway. J Immunol 1999, 163(1):224-231.
35. Klinman DM. Use of CpG oligodeoxynucleotides as immunoprotective agents. Expert Opin Biol Ther 2004, 4(6):937-946. 10.1517/14712598.4.6.937, 15174975.
36. Krieg AM. Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc 2007, 4(3):289-294. 10.1513/pats.200701-021AW, 2647632, 17607015.
37. Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax 1993, 48(10):959-966. 10.1136/thx.48.10.959, 464798, 7504843.